Literature DB >> 28337685

Type III Hypersensitivity Reaction to Subcutaneous Insulin Preparations in a Type 1 Diabetic.

Benjamin R Murray1, Jolene R Jewell1, Kyle J Jackson1, Olabunmi Agboola1, Brianna R Alexander2, Poonam Sharma3.   

Abstract

Management of type 1 diabetes in patients who have insulin hypersensitivity is a clinical challenge and places patients at risk for recurrent diabetic ketoacidosis (DKA). Hypersensitivity reactions can be due to the patient's response to the insulin molecule itself or one of the injection's non-insulin components. It is therefore crucial for clinicians to quickly recognize the type of hypersensitivity reaction that is occurring and identify potentially immunogenic additives for the purpose of directing therapy as various insulin preparations have differing ingredients. We present the case of a 23-year-old diabetic female with common variable immunodeficiency (CVID) and autoimmune enteropathy who developed a type III hypersensitivity reaction to multiple formulations of subcutaneous insulin after years of use and the challenges of devising a long-term management strategy.

Entities:  

Keywords:  insulin allergy; insulin hypersensitivity; type III hypersensitivity

Mesh:

Substances:

Year:  2017        PMID: 28337685      PMCID: PMC5481240          DOI: 10.1007/s11606-017-4037-7

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  19 in total

1.  The incidence of skin reactivity to insulin in diabetic patients.

Authors:  J A ARKINS; N H ENGBRING; E J LENNON
Journal:  J Allergy       Date:  1962 Jan-Feb

2.  Refractory insulin allergy: pancreas transplantation or immunosuppressive therapy alone?

Authors:  Jacqueline Léonet; Jacques Malaise; Jean-Paul Squifflet
Journal:  Transpl Int       Date:  2010-03-11       Impact factor: 3.782

3.  Type III hypersensitivity to insulin leading to leukocytoclastic vasculitis.

Authors:  B Rachid; M Rabelo-Santos; E Mansour; R de Lima Zollner; L A Velloso
Journal:  Diabetes Res Clin Pract       Date:  2010-06-16       Impact factor: 5.602

Review 4.  Insulin allergy.

Authors:  Mohammad K Ghazavi; Graham A Johnston
Journal:  Clin Dermatol       Date:  2011 May-Jun       Impact factor: 3.541

5.  Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion.

Authors:  V Moyes; R Driver; A Croom; R Mirakian; T A Chowdhury
Journal:  Diabet Med       Date:  2006-02       Impact factor: 4.359

6.  Dermal reactions to insulin therapy.

Authors:  R PALEY; R TUNBRIDGE
Journal:  Diabetes       Date:  1952 Jan-Feb       Impact factor: 9.461

7.  Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia.

Authors:  Thomas Mandrup-Poulsen; Jens Mølvig; Julie Pildal; Ase Krogh Rasmussen AK; Lennart Andersen; Birgit Guldhammer Skov; Jørgen Petersen
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

8.  Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.

Authors:  Susan J Logtenberg; Nanne Kleefstra; Sebastiaan T Houweling; Klaas H Groenier; Reinold O Gans; Evert van Ballegooie; Henk J Bilo
Journal:  Diabetes Care       Date:  2009-05-08       Impact factor: 17.152

9.  Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes.

Authors:  S Marusic; V Vlahovic-Palcevski; D Ljubanovic
Journal:  Int J Clin Pharmacol Ther       Date:  2009-10       Impact factor: 1.366

Review 10.  New forms of insulin and insulin therapies for the treatment of type 2 diabetes.

Authors:  Avivit Cahn; Roberto Miccoli; Angela Dardano; Stefano Del Prato
Journal:  Lancet Diabetes Endocrinol       Date:  2015-06-04       Impact factor: 32.069

View more
  1 in total

Review 1.  Insulin Allergy to Detemir Followed by Rapid Onset of Diabetic Ketoacidosis: A Case Report and Literature Review.

Authors:  Chong Boon Teo; Pek Yan Tan; Shan Xian Lee; Joan Khoo; Jun Guan Tan; Su Fen Ang; Sze Hwa Tan; Tunn Lin Tay; Eberta Tan; Su Chi Lim; Bernhard O Boehm; Wann Jia Loh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.